Ironwood Pharmaceuticals (IRWD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

IRWD · Stock Price

USD 4.17+3.46 (+487.32%)

Market Cap: $693.8M

Historical price data

Overview

Ironwood Pharmaceuticals is a mission-driven, publicly traded biotech dedicated to advancing the treatment of gastrointestinal diseases and redefining the standard of care. Its cornerstone achievement is the discovery, development, and commercialization of the first-in-class GC-C agonist LINZESS® (linaclotide), a blockbuster therapy for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company's strategy centers on leveraging its proprietary GI platforms, commercial infrastructure, and deep scientific expertise to build a pipeline targeting organic GI diseases with high unmet need, including the late-stage development of apraglutide for short bowel syndrome.

Gastroenterology

Technology Platform

Ironwood's competitive advantage is built on two proprietary platforms: the guanylate cyclase-C (GC-C) receptor agonist platform, which led to linaclotide, and the glucagon-like peptide-2 (GLP-2) analog platform, which underpins apraglutide.

Pipeline

33

33 drugs in pipeline11 in Phase 3

Drug	Indication	Stage
Linaclotide	Irritable Bowel Syndrome With Constipation	Approved
Linaclotide + Placebo	Irritable Bowel Syndrome Characterized by Constipation	Approved
Linaclotide 290 micrograms + Linaclotide 145 micrograms + Pl...	Chronic Constipation	Phase 3
Matching Placebo + Linaclotide	Chronic Constipation	Phase 3
Linaclotide	Irritable Bowel Syndrome With Constipation	Phase 3

Opportunities

The near-term opportunity is the planned NDA submission and potential 2026/2027 launch of apraglutide for Short Bowel Syndrome, which could diversify revenue and establish Ironwood in the rare disease space.

Longer-term, success in the Phase 2 aGVHD trial and advancement of the GC-C research platform offer additional growth avenues.

Risk Factors

Key risks include regulatory or commercial execution failure for apraglutide, which is critical for near-term growth, and over-reliance on the maturing LINZESS franchise, which faces ongoing competitive and potential future generic pressures.

Competitive Landscape

LINZESS competes in a crowded CIC/IBS-C market against other prescription therapies. Apraglutide's primary competitor in SBS-IF is Takeda's daily-injected teduglutide, against which apraglutide's once-weekly dosing is a key potential differentiator.

More companies in Small Molecule Drugs →More companies in United States →